These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 31903146)
1. Amplification-driven BCL6-suppressed cytostasis is mediated by transrepression of FOXO3 and post-translational modifications of FOXO3 in urinary bladder urothelial carcinoma. Wu WR; Lin JT; Pan CT; Chan TC; Liu CL; Wu WJ; Sheu JJ; Yeh BW; Huang SK; Jhung JY; Hsiao MS; Li CF; Shiue YL Theranostics; 2020; 10(2):707-724. PubMed ID: 31903146 [TBL] [Abstract][Full Text] [Related]
2. EMP2 induces cytostasis and apoptosis via the TGFβ/SMAD/SP1 axis and recruitment of P2RX7 in urinary bladder urothelial carcinoma. Li CF; Chan TC; Pan CT; Vejvisithsakul PP; Lai JC; Chen SY; Hsu YW; Shiao MS; Shiue YL Cell Oncol (Dordr); 2021 Oct; 44(5):1133-1150. PubMed ID: 34339014 [TBL] [Abstract][Full Text] [Related]
3. ABT-751 Induces Multiple Anticancer Effects in Urinary Bladder Urothelial Carcinoma-Derived Cells: Highlighting the Induction of Cytostasis through the Inhibition of Dehghanian SZ; Pan CT; Lee JM; Shiue YL Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33478005 [TBL] [Abstract][Full Text] [Related]
4. CEBPD amplification and overexpression in urothelial carcinoma: a driver of tumor metastasis indicating adverse prognosis. Wang YH; Wu WJ; Wang WJ; Huang HY; Li WM; Yeh BW; Wu TF; Shiue YL; Sheu JJ; Wang JM; Li CF Oncotarget; 2015 Oct; 6(31):31069-84. PubMed ID: 26307680 [TBL] [Abstract][Full Text] [Related]
5. Influence of Casein kinase II inhibitor CX-4945 on BCL6-mediated apoptotic signaling in B-ALL in vitro and in vivo. Richter A; Sender S; Lenz A; Schwarz R; Hinz B; Knuebel G; Sekora A; Murua Escobar H; Junghanss C; Roolf C BMC Cancer; 2020 Mar; 20(1):184. PubMed ID: 32131762 [TBL] [Abstract][Full Text] [Related]
6. IGFBP-5 overexpression as a poor prognostic factor in patients with urothelial carcinomas of upper urinary tracts and urinary bladder. Liang PI; Wang YH; Wu TF; Wu WR; Liao AC; Shen KH; Hsing CH; Shiue YL; Huang HY; Hsu HP; Chen LT; Lin CY; Tai C; Wu JY; Li CF J Clin Pathol; 2013 Jul; 66(7):573-82. PubMed ID: 23539739 [TBL] [Abstract][Full Text] [Related]
7. Transmembrane and Coiled-Coil Domain 1 Impairs the AKT Signaling Pathway in Urinary Bladder Urothelial Carcinoma: A Characterization of a Tumor Suppressor. Li CF; Wu WR; Chan TC; Wang YH; Chen LR; Wu WJ; Yeh BW; Liang SS; Shiue YL Clin Cancer Res; 2017 Dec; 23(24):7650-7663. PubMed ID: 28972042 [No Abstract] [Full Text] [Related]
8. The cAMP responsive element binding protein 1 transactivates epithelial membrane protein 2, a potential tumor suppressor in the urinary bladder urothelial carcinoma. Li CF; Wu WJ; Wu WR; Liao YJ; Chen LR; Huang CN; Li CC; Li WM; Huang HY; Chen YL; Liang SS; Chow NH; Shiue YL Oncotarget; 2015 Apr; 6(11):9220-39. PubMed ID: 25940704 [TBL] [Abstract][Full Text] [Related]
9. MicroRNA-608 inhibits proliferation of bladder cancer via AKT/FOXO3a signaling pathway. Liang Z; Wang X; Xu X; Xie B; Ji A; Meng S; Li S; Zhu Y; Wu J; Hu Z; Lin Y; Zheng X; Xie L; Liu B Mol Cancer; 2017 May; 16(1):96. PubMed ID: 28549468 [TBL] [Abstract][Full Text] [Related]
10. Importin-11 overexpression promotes the migration, invasion, and progression of bladder cancer associated with the deregulation of CDKN1A and THBS1. Zhao J; Shi L; Zeng S; Ma C; Xu W; Zhang Z; Liu Q; Zhang P; Sun Y; Xu C Urol Oncol; 2018 Jun; 36(6):311.e1-311.e13. PubMed ID: 29602637 [TBL] [Abstract][Full Text] [Related]
11. Epigenetic silencing of the dual-role signal mediator, ANGPTL4 in tumor tissues and its overexpression in the urothelial carcinoma microenvironment. Hsieh HY; Jou YC; Tung CL; Tsai YS; Wang YH; Chi CL; Lin RI; Hung SK; Chuang YM; Wu SF; Li C; Shen CH; Chan MWY; Hsu CD Oncogene; 2018 Feb; 37(5):673-686. PubMed ID: 29035390 [TBL] [Abstract][Full Text] [Related]
12. The tumor-suppressor gene Nkx2.8 suppresses bladder cancer proliferation through upregulation of FOXO3a and inhibition of the MEK/ERK signaling pathway. Yu C; Zhang Z; Liao W; Zhao X; Liu L; Wu Y; Liu Z; Li Y; Zhong Y; Chen K; Li J; Zhou F; Song L Carcinogenesis; 2012 Mar; 33(3):678-86. PubMed ID: 22223847 [TBL] [Abstract][Full Text] [Related]
13. ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression. Kawahara T; Shareef HK; Aljarah AK; Ide H; Li Y; Kashiwagi E; Netto GJ; Zheng Y; Miyamoto H Oncotarget; 2015 Oct; 6(30):29860-76. PubMed ID: 26342199 [TBL] [Abstract][Full Text] [Related]
14. Correlations of Foxo3 and Foxo4 expressions with clinicopathological features and prognosis of bladder cancer. Wang Y; Kang XL; Zeng FC; Xu CJ; Zhou JQ; Luo DN Pathol Res Pract; 2017 Jul; 213(7):766-772. PubMed ID: 28554751 [TBL] [Abstract][Full Text] [Related]
15. Sulfatase-1 overexpression indicates poor prognosis in urothelial carcinoma of the urinary bladder and upper tract. Lee HY; Yeh BW; Chan TC; Yang KF; Li WM; Huang CN; Ke HL; Li CC; Yeh HC; Liang PI; Shiue YL; Wu WJ; Li CF Oncotarget; 2017 Jul; 8(29):47216-47229. PubMed ID: 28525382 [TBL] [Abstract][Full Text] [Related]
16. High expression of Chitinase 3-like-1 is an unfavorable prognostic factor in urothelial carcinoma of upper urinary tract and urinary bladder. Lee YE; Chan TC; Tian YF; Liang PI; Shiue YL; Chen YS; He HL Urol Oncol; 2019 May; 37(5):299.e7-299.e18. PubMed ID: 30660494 [TBL] [Abstract][Full Text] [Related]
17. SLC14A1 prevents oncometabolite accumulation and recruits HDAC1 to transrepress oncometabolite genes in urothelial carcinoma. Chan TC; Wu WJ; Li WM; Shiao MS; Shiue YL; Li CF Theranostics; 2020; 10(25):11775-11793. PubMed ID: 33052246 [TBL] [Abstract][Full Text] [Related]
18. Overexpression of HepaCAM inhibits bladder cancer cell proliferation and viability through the AKT/FoxO pathway. Tang M; Zhao Y; Liu N; Chen E; Quan Z; Wu X; Luo C J Cancer Res Clin Oncol; 2017 May; 143(5):793-805. PubMed ID: 28229220 [TBL] [Abstract][Full Text] [Related]
19. Promoter hypomethylation mediated upregulation of MicroRNA-10b-3p targets FOXO3 to promote the progression of esophageal squamous cell carcinoma (ESCC). Lu YF; Yu JR; Yang Z; Zhu GX; Gao P; Wang H; Chen SY; Zhang J; Liu MY; Niu Y; Wei XM; Wang W; Ye FJ; Zhang LX; Zhao Y; Sun GG J Exp Clin Cancer Res; 2018 Dec; 37(1):301. PubMed ID: 30514328 [TBL] [Abstract][Full Text] [Related]
20. Upregulation of dihydropyrimidinase-like 3 (DPYSL3) protein predicts poor prognosis in urothelial carcinoma. Liang PI; Lai HY; Chan TC; Li WM; Hsing CH; Huang SK; Hsieh KL; Tseng WH; Chen TJ; Li WS; Chen HD; Kuo YH; Li CF BMC Cancer; 2023 Jun; 23(1):599. PubMed ID: 37380971 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]